249 related articles for article (PubMed ID: 12813634)
21. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in diagnosis and management of pancreatic cancer; comparison with multidetector row computed tomography, magnetic resonance imaging and endoscopic ultrasonography.
Ergul N; Gundogan C; Tozlu M; Toprak H; Kadıoglu H; Aydin M; Cermik TF
Rev Esp Med Nucl Imagen Mol; 2014; 33(3):159-64. PubMed ID: 24140024
[TBL] [Abstract][Full Text] [Related]
22. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
[TBL] [Abstract][Full Text] [Related]
23. [Can the extent of pancreatic tumors be evaluated reliably enough by positron emission tomography (PET)].
Sendler A; Avril N; Roder JD; Schwaiger M; Siewert JR
Langenbecks Arch Chir Suppl Kongressbd; 1998; 115():1485-7. PubMed ID: 9931919
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of pancreatic tumors with positron emission tomography and F-18 fluorodeoxyglucose: comparison with CT and US.
Inokuma T; Tamaki N; Torizuka T; Magata Y; Fujii M; Yonekura Y; Kajiyama T; Ohshio G; Imamura M; Konishi J
Radiology; 1995 May; 195(2):345-52. PubMed ID: 7724751
[TBL] [Abstract][Full Text] [Related]
25. The role of fluorodeoxyglucose and positron emission tomography in the evaluation of pancreatic disease.
Rajput A; Stellato TA; Faulhaber PF; Vesselle HJ; Miraldi F
Surgery; 1998 Oct; 124(4):793-7; discussion 797-8. PubMed ID: 9781003
[TBL] [Abstract][Full Text] [Related]
26. Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases.
Zimny M; Bares R; Fass J; Adam G; Cremerius U; Dohmen B; Klever P; Sabri O; Schumpelick V; Buell U
Eur J Nucl Med; 1997 Jun; 24(6):678-82. PubMed ID: 9169578
[TBL] [Abstract][Full Text] [Related]
27. Imaging of oncologic patients: benefit of combined CT and FDG PET in the diagnosis of malignancy.
Eubank WB; Mankoff DA; Schmiedl UP; Winter TC; Fisher ER; Olshen AB; Graham MM; Eary JF
AJR Am J Roentgenol; 1998 Oct; 171(4):1103-10. PubMed ID: 9763005
[TBL] [Abstract][Full Text] [Related]
28. Diagnosis of pancreatic carcinoma: role of FDG PET.
Keogan MT; Tyler D; Clark L; Branch MS; McDermott VG; DeLong DM; Coleman RE
AJR Am J Roentgenol; 1998 Dec; 171(6):1565-70. PubMed ID: 9843289
[TBL] [Abstract][Full Text] [Related]
29. [Results of positron emission tomography with fluorine-18 labeled fluorodeoxyglucose in differential diagnosis and staging of pancreatic carcinoma].
Bares R; Dohmen BM; Cremerius U; Fass J; Teusch M; Büll U
Radiologe; 1996 May; 36(5):435-40. PubMed ID: 8778929
[TBL] [Abstract][Full Text] [Related]
30. Positron emission tomographic imaging with fluorodeoxyglucose isefficacious in evaluating malignant pulmonary disease.
Graeber GM; Gupta NC; Murray GF
J Thorac Cardiovasc Surg; 1999 Apr; 117(4):719-27. PubMed ID: 10096967
[TBL] [Abstract][Full Text] [Related]
31. 18-Fluorodeoxyglucose positron emission tomography does not aid in diagnosis of pancreatic ductal adenocarcinoma.
Matsumoto I; Shirakawa S; Shinzeki M; Asari S; Goto T; Ajiki T; Fukumoto T; Kitajima K; Ku Y
Clin Gastroenterol Hepatol; 2013 Jun; 11(6):712-8. PubMed ID: 23353642
[TBL] [Abstract][Full Text] [Related]
32. FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation.
Anderson GS; Brinkmann F; Soulen MC; Alavi A; Zhuang H
Clin Nucl Med; 2003 Mar; 28(3):192-7. PubMed ID: 12592125
[TBL] [Abstract][Full Text] [Related]
33. Delayed (18)F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas.
Nakamoto Y; Higashi T; Sakahara H; Tamaki N; Kogire M; Doi R; Hosotani R; Imamura M; Konishi J
Cancer; 2000 Dec; 89(12):2547-54. PubMed ID: 11135214
[TBL] [Abstract][Full Text] [Related]
34. Diagnosis of pancreatic cancer by 2[18F]-fluoro-2-deoxy-D-glucose positron emission tomography.
Friess H; Langhans J; Ebert M; Beger HG; Stollfuss J; Reske SN; Büchler MW
Gut; 1995 May; 36(5):771-7. PubMed ID: 7797130
[TBL] [Abstract][Full Text] [Related]
35. FDG PET: elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies.
Diederichs CG; Staib L; Glatting G; Beger HG; Reske SN
J Nucl Med; 1998 Jun; 39(6):1030-3. PubMed ID: 9627339
[TBL] [Abstract][Full Text] [Related]
36. Ki-67 immunostaining in pancreatic cancer and chronic active pancreatitis: does in vivo FDG uptake correlate with proliferative activity?
Buck AC; Schirrmeister HH; Guhlmann CA; Diederichs CG; Shen C; Buchmann I; Kotzerke J; Birk D; Mattfeldt T; Reske SN
J Nucl Med; 2001 May; 42(5):721-5. PubMed ID: 11337566
[TBL] [Abstract][Full Text] [Related]
37. [The application of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer].
Xu HF; Liu Y; Zhang JH; Zhou RS; Zhou FH; Yuan MH
Zhonghua Jie He He Hu Xi Za Zhi; 2005 Feb; 28(2):108-11. PubMed ID: 15854393
[TBL] [Abstract][Full Text] [Related]
38. Differentiation of autoimmune pancreatitis from suspected pancreatic cancer by fluorine-18 fluorodeoxyglucose positron emission tomography.
Ozaki Y; Oguchi K; Hamano H; Arakura N; Muraki T; Kiyosawa K; Momose M; Kadoya M; Miyata K; Aizawa T; Kawa S
J Gastroenterol; 2008; 43(2):144-51. PubMed ID: 18306988
[TBL] [Abstract][Full Text] [Related]
39. FDG-PET evaluation of indeterminate pancreatic masses.
Ho CL; Dehdashti F; Griffeth LK; Buse PE; Balfe DM; Siegel BA
J Comput Assist Tomogr; 1996; 20(3):363-9. PubMed ID: 8626891
[TBL] [Abstract][Full Text] [Related]
40. Pancreatic tumors: role of imaging in the diagnosis, staging, and treatment.
Delbeke D; Pinson CW
J Hepatobiliary Pancreat Surg; 2004; 11(1):4-10. PubMed ID: 15747028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
